CM&R HMO Research Network 2008 conference proceedings and abstracts NOW ONLINE!
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Medicine & Research
Volume 3, Number 4 : 221 -228
doi:10.3121/cmr.3.4.221
© 2005 Marshfield Clinic
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Raez, L. E.
Right arrow Articles by Podack, E. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Raez, L. E.
Right arrow Articles by Podack, E. R.

Review

Lung Cancer Immunotherapy

Luis E. Raez, MD, Steven Fein, MD and Eckhard R. Podack, MD

Luis E. Raez, MD, FACP, Epidemiology and Public Health, Sylvester Comprehensive Cancer Center, University of Miami School of Medicine, Miami, Florida
Steven Fein, MD, MPH, Division of Hematology/Oncology, Sylvester Comprehensive Cancer Center, University of Miami School of Medicine, Miami, Florida
Eckhard R. Podack, MD, Department of Microbiology and Immunology, University of Miami School of Medicine, Sylvester Comprehensive Cancer Center, Miami, Florida

Reprint Requests: Luis E. Raez, MD, Epidemiology and Public Health, Sylvester Comprehensive Cancer Center, University of Miami School of Medicine, 1475 NW 12 Avenue, #3510, Miami, FL 33136, Tel: 305-243-6644, Fax: 305-243-5326, E-mail: lraez{at}med.miami.edu

Recent insights into anti-tumor immunotherapy have led to a wave of clinical trials involving immunotherapy for lung cancer. Vaccines have evolved from nonspecific immune stimulants, like Bacillus Calmette-Guerin (BCG), to much more specific and potent strategies, some of which generate active immune responses against tumor-associated antigens. Understanding the mechanisms of anti-tumor immunity and identifying target antigens will likely improve these therapeutic strategies and provide them with a niche in the future of lung cancer therapy.

Key Words: Immunotherapy • Non-small cell lung cancer • Small cell lung cancer • Tumor immunology • Tumor vaccines




This article has been cited by other articles:


Home page
 Proc Am Thorac SocHome page
E. A. Hirschowitz and J. R. Yannelli
Immunotherapy for Lung Cancer
Proceedings of the ATS, April 15, 2009; 6(2): 224 - 232.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. F. Cheung, M. J.P. DuPage, H. K. Dong, J. Chen, and T. Jacks
Regulated Expression of a Tumor-Associated Antigen Reveals Multiple Levels of T-Cell Tolerance in a Mouse Model of Lung Cancer
Cancer Res., November 15, 2008; 68(22): 9459 - 9468.
[Abstract] [Full Text] [PDF]

Home page
 CVIHome page
A. Sharma, A. Saha, S. Bhattacharjee, S. Majumdar, and S. K. Das Gupta
Specific and Randomly Derived Immunoactive Peptide Mimotopes of Mycobacterial Antigens
Clin. Vaccine Immunol., October 1, 2006; 13(10): 1143 - 1154.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2005 by Marshfield Clinic.